Objective: The treatment for arch aneurysms by endovascular repair is often difficult. This study evaluated the long-term outcomes of thoracic endovascular aortic repair for aortic arch aneurysms treated with the Najuta stent-graft system.

Materials and Methods: From January 2009 to December 2019, 37 patients underwent treatment for aortic aneurysms with the Najuta stent graft system at two institutes, including our hospital. We retrospectively analyzed the short- and long-term clinical outcomes.

Results: Of all 37 cases, the technical success rate was 97.3% (36 of 37). The mean proximal neck length was 20.1±5.3 mm. The postoperative results revealed 10 patients with type Ia endoleaks (27.8%), 6 with stroke (16.7%), and one with paraplegia (2.8%). In the chronic phase, the overall survival rates and the rates of freedom from aorta-related events at 7 years were 71.3% and 50.7%, respectively. Between two groups divided based on the proximal neck diameter of 20 mm, the <20-mm group had significantly higher rates of aorta-related events in terms of freedom from aortic events (P=0.046).

Conclusion: The fenestrated stent graft can be a less invasive option for the treatment of high-risk patients with aortic aneurysms.

Keywords: thoracic endovascular aortic repair (TEVAR), arch aneurysm, fenestrated stent graft

Introduction

Recently, thoracic endovascular aortic repair (TEVAR) has been established as the gold standard surgery for descending aortic aneurysms because it has shown very effective long-term outcomes.1-3) However, an aortic arch aneurysm is often difficult to treat with TEVAR because of the arch curvature and the presence of supra-aortic vessels, so the first-line surgical treatment for arch aneurysms has been graft replacement, until now.4) Although TEVAR is alternatively selected for high-risk patients in whom it is impossible to perform graft replacement, most of them are considered as very difficult cases for endograft repair because of the need for zone 0 or 1 proximal stent graft landing.5) Several surgical techniques for arch aneurysms that require zone 0–1 landing have been reported, one of which is the Najuta thoracic stent-graft system. This fenestrated stent graft is a semicustom device made using preoperative three-dimensional computed tomography (CT) and can be utilized by deploying on the arch aorta without reconstruction for supra-aortic vessels because of the fenestration on the device.6,7) Although this device allows for a less invasive and simple surgical procedure, device-specific disadvantages, such as low flexibility and low radial force, have been reported.8) Its long-term clinical results are unclear and not well reported. The present study evaluated the clinical outcomes of TEVAR using the Najuta stent-graft system for aortic arch aneurysms that require zone 0–1 landing. This study has been approved by IRB of Otaru General Hospital, with approval number 02-003.
Materials and Methods

Patients
Patients who underwent TEVAR using the Najuta stent-graft system for arch aneurysms at two institutions, Otaru General Hospital and Sapporo Medical University School of Medicine, between January 2009 and December 2019 were included in the present study. Before the procedure, we obtained written informed consent from all patients. The proximal neck length was defined as the direct length from the origin of the preserving vessel to the proximal edge of the aneurysm, which was the site along the aortic wall.

Surgical procedures
The details of the Najuta stent graft and procedure have been reported previously by Yokoi et al.9) The common femoral artery was used as the access artery in all cases. The stent graft was inserted using a tug-of-wire method to avoid excessive arterial injury. The device was deployed under fluoroscopic guidance without additional circulatory support. Postdeployment touch-up ballooning was performed as required. The left subclavian artery (LSCA) was revascularized in selected patients, such as those at high risk of spinal cord ischemia.

Definition and end points
The significant change of the aneurysmal diameter was defined as >5 mm from the first postoperative CT. The end points of this study included technical success, complications, overall survival rates, and rates of freedom from aorta-related events, including aneurysmal enlargement, stent-graft migration, rupture, and retrograde type A dissection (RTAD).

Statistical analysis
The overall survival rates and the rates of freedom from aorta-related events were assessed using the Kaplan–Meier method. Furthermore, the rates of aorta-related events were compared using the log-rank test between two groups that were divided based on the proximal neck length of 20 mm. The logistic regression model was used to identify predominant risk factors of type Ia endoleak and stroke. The best model was selected by the backward step-down selection using the Akaike Information Criteria. All data analyses were performed using the statistical program R, version 3.2.1 (R Foundation for Statistical Computing; http://www.r-project.org/).

Results

Patients’ characteristics, aneurysmal configuration, and operative outcomes
Of all 37 patients, 29 were males (78.4%), and the mean age was 77.3 ± 7.1 years. The mean follow-up period was 2.9 ± 2.9 years. All the cases were considered as high risk for open surgical graft replacement. The patients’ characteristics are shown in Table 1. Regarding aneurysm configurations, the number of fusiform aneurysms was 20 (54.1%), that of saccular aneurysms was 13 (35.1%), that of true aneurysms was 33 (89.2%), and that of dissection was 4 (10.8%). The mean maximum aneurysmal diameter was 57.1 ± 14.4 mm. The mean proximal neck length was 20.1 ± 5.3 mm. The technical success rate was 97.3% (36 of 37; in one case, a guide wire got stuck in the main stent-graft device). The proximal landing zone of the stent graft was located at zone 0 in 31 patients (86.1%), zone 1 in 5 patients (13.9%), and zone 2 and 3–4 in 0 patients (0%). The fenestrated proximal neck vessel was the brachiocephalic artery (BCA) in 33 patients (91.7%), the left common carotid artery (LCCA) in 35 patients (97.2%),

Table 1 Patients’ characteristics

| Variable                        | Value       |
|--------------------------------|-------------|
| Age (years)                    | 77.3±7.1    |
| Sex (male)                     | 29 (78.4%)  |
| Medical history                |             |
| Hypertension                   | 28 (77.8)   |
| Dyslipidemia                   | 6 (16.2)    |
| Diabetes mellitus              | 11 (29.7)   |
| COPD                           | 7 (18.9)    |
| Coronary artery disease        | 10 (27.0)   |
| Cerebrovascular disease        | 5 (33.3)    |
| CKD                            | 4 (10.8)    |
| Arrhythmia                     | 4 (10.8)    |
| Previous cardiovascular surgery| 14 (37.8)   |
| History of cancer              | 8 (21.6)    |
| EuroSCORE II                   | 18.6±8.8    |
| Etiology                       |             |
| Degenerative aneurysm          |             |
| Fusiform                       | 20 (54.1)   |
| Saccular                       | 13 (35.1)   |
| Dissection                     | 4 (10.8)    |
| Aneurysm diameter (mm)         | 57.1±14.4   |
| Aneurysm length (mm)           | 50.7±16.1   |
| Proximal neck diameter (mm)    | 34.7±3.9    |
| Distal neck diameter (mm)      | 29.5±3.4    |
| Proximal neck length (mm)      | 20.1±5.3    |

The data are presented as the mean±standard deviation (SD) or n (%). COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; EuroSCORE: European system for cardiac operative risk evaluation.
the LSCA in 8 patients (22.2%), and LSCA reconstruction in 16 patients (44.4%) (Table 2).

**Short- and long-term outcomes**

In the postoperative results, six patients had strokes (16.7%) and one had paraplegia (2.8%). There was neither stent-induced new entry nor RTAD. Type Ia endoleaks were recognized in 10 patients (27.8%). The in-hospital mortality was 0%. In the chronic phase, the aneurysmal size shrank in 11 patients (30.6%), there was no change in 15 patients (41.7%), and it was enlarged in 10 patients (27.8%). Four patients died during the follow-up owing to malignant tumors (2), RTAD (1), and unknown cause (1) (Table 2). Three patients underwent reinterventions, which consisted of coil embolization (two patients) and re-TEVAR for stent graft migration (one patient).

Discussion

Graft replacement for arch aneurysms with cardiopulmonary bypass can be difficult to perform in patients with poor health conditions, as it is a highly invasive procedure. Although endovascular therapy is selected for these patients, it is important to consider the long-term outcomes, including the rates of type Ia endoleaks, stroke, and paraplegia. The Kaplan–Meier curves (Fig. 1) show the overall survival rates and the rates of freedom from aorta-related events after TEVAR using the Najuta fenestrated stent-graft system. The results of the univariate and multivariate logistic regression analyses revealed that the proximal neck length was the risk factor for type Ia endoleak, and previous stroke and diabetes mellitus were detected as risk factors for stroke (Table 3).
Clinical Outcomes of the Najuta Stent-Graft System

Table 3 Risk factors for type Ia endoleak and stroke identified by univariate and multivariate logistic regression analyses

| Dependent variable | Independent variables | Univariate | Multivariate |
|-------------------|-----------------------|------------|-------------|
|                   |                       | OR (95%CI) | P-value     | OR (95%CI) | P-value |
| Type Ia endoleak  | Age (years)           | 0.985 (0.89–1.09) | 0.763 |          |          |
|                   | Sex (male)            | 0.556 (0.11–2.94) | 0.49 |          |          |
|                   | Arrhythmia            | 0.852 (0.08–9.3)  | 0.895 |          |          |
|                   | Chronic kidney disease| 3 (0.36–24.9)    | 0.309 |          |          |
|                   | Chronic obstructive pulmonary disease | 0.37 (0.04–3.54) | 0.389 |          |          |
|                   | Dyslipidemia          | 3.29 (0.54–20.1)  | 0.198 |          |          |
|                   | Diabetes mellitus     | 2.22 (0.47–10.6)  | 0.316 |          |          |
|                   | Hypertension          | 2.1 (0.5–5.6)     | 0.994 |          |          |
|                   | Coronary artery disease| 0.25 (0.04–2.32) | 0.223 |          |          |
|                   | Previous stroke       | 2.25 (0.51–10)    | 0.287 |          |          |
|                   | Previous cardiovascular surgery | 4.07 (0.88–18.9) | 0.0727 |          |          |
|                   | Fusiform              | 1.29 (0.29–5.66)  | 0.031 |          |          |
|                   | Aneurysm diameter (mm) | 0.996 (0.95–1.05) | 0.866 |          |          |
|                   | Aneurysm length (mm)  | 1 (0.95–1.05)     | 0.977 |          |          |
|                   | Proximal neck length (mm) | 0.828 (0.68–1.01) | 0.021 | 0.83 (0.68–0.95) | 0.039 |
|                   | Proximal neck diameter (mm) | 1.14 (0.93–1.41) | 0.039 |          |          |
|                   | LSCA reconstruction   | 1.36 (0.32–5.9)   | 0.678 |          |          |
|                   | Proximal fenestrated vessel (BCA, LCCA, LSCA) | 0.7 (0.1–1.3) | 0.98 |          |          |
| Stroke            | Age (years)           | 0.958 (0.85–1.08) | 0.47 |          |          |
|                   | Sex (male)            | 1.52 (0.15–15.3)  | 0.72 |          |          |
|                   | Arrhythmia            | 1.8 (0.15–21)     | 0.64 |          |          |
|                   | Chronic kidney disease| 1.8 (0.15–21)     | 0.64 |          |          |
|                   | Chronic obstructive pulmonary disease | 0.8 (0.08–8.19) | 0.85 |          |          |
|                   | Dyslipidemia          | 1 (0.1–10.5)      | 1.00 |          |          |
|                   | Diabetes mellitus     | 25 (2.38–263)     | 0.007 | 2.5 (1.38–5.1) | 0.007 |
|                   | Hypertension          | 1.59 (0.16–16)    | 0.69 |          |          |
|                   | Coronary artery disease| 1.64 (0.25–10.9) | 0.61 |          |          |
|                   | Previous stroke       | 18 (3.4–11.8)     | 0.003 | 2.4 (1.2–4.9) | 0.015 |
|                   | Previous cardiovascular surgery | 2 (0.34–11.8) | 0.44 |          |          |
|                   | Fusiform              | 0.765 (0.13–4.43) | 0.77 |          |          |
|                   | Aneurysm diameter (mm) | 1.01 (0.95–1.07) | 0.80 |          |          |
|                   | Aneurysm length (mm)  | 1 (0.94–1.06)     | 1.00 |          |          |
|                   | Proximal neck length (mm) | 1.05 (0.9–1.23) | 0.55 |          |          |
|                   | Proximal neck diameter (mm) | 0.823 (0.62–1.1) | 0.19 |          |          |
|                   | LSCA reconstruction   | 3 (0.47–19)       | 0.24 |          |          |
|                   | Proximal fenestrated vessel (BCA, LCCA, LSCA) | 0.8 (0.1–1.2) | 0.99 |          |          |
|                   | Blood loss (ml)       | 0.72 (0.72–1.6)   | 0.56 |          |          |
|                   | Packed red blood cells (ml) | 0.82 (0.65–1.8) | 0.66 |          |          |

OR: odds ratio; CI: confidence interval; BCA: brachiocephalic artery; LCCA: left common carotid artery; LSCA: left subclavian artery

patients, TEVAR, which has shown effective results in the treatment of descending aortic aneurysms, is not always good for the treatment of arch aneurysms. This is because of the difficulty of device fitting in the arch curvature and the insufficient proximal landing length owing to the presence of supra-aortic branches. These difficulties can be the causes of the incidence of endoleaks and later aneurysmal enlargement.

Surgical procedures, such as the chimney technique and debranched technique, have been reported to preserve the supra-aortic branch blood flow with TEVAR from zone 0 to 1. Either of these techniques can treat arch aneurysms without graft replacement. However, in the chimney technique, type Ia endoleak may occur because of the gap between the chimney graft and the main graft. Thus, the rate of type Ia endoleaks has been reported from 19.7% to 40.0%.10,11) In contrast, in the debranched technique, a sufficient proximal landing length can be achieved by branch bypass, but the surgical procedure for BCA or LCCA can cause cerebral infarction, which has been reported in 11.4%–26.9% cases.4,12,13) Thus, these techniques can be surgical options for arch aneurysms, but not
first-line treatments.

The precurved Najuta fenestrated endograft was developed to solve these clinical issues in a completely endovascular manner.\(^9\) The incidence of cerebral infarction was reported to be 0%–5.4%, which is lower than, and superior to, the other abovementioned techniques.\(^5,8,14\) However, there are structural device disadvantages, such as the lack of conformability of stents 25 mm in length and low radial force by the absence of the stent at the fenestrated lesion. Even if the proximal landing is from the ascending aorta, the proximal sealing can often be inadequate. For this reason, the incidence of type I endoleaks was higher than that of other devices, which has been reported to be 4.2%–32.4%.\(^5,9,14\) In the study of Kurimoto et al., which summarized the results of treatment using the Najuta stent graft for 37 patients with arch aneurysms, the incidence of type I endoleaks was 32.4%, and the rates of freedom from aorta-related events at 2 and 5 years were 88.5% and 56.5%, respectively.\(^14\) In the present study, these results are almost the same: the incidence of type I endoleaks was 27.8%, and the rates of freedom from aorta-related events at 2 and 5 years were 81.0% and 50.7%, respectively. Furthermore, the group with the proximal neck length <20 mm showed a higher rate of aortic events in the chronic phase. Further, a short proximal neck length was identified as an independent risk factor of type I endoleaks (Table 3). This is because a length <20 mm is inadequate as proximal sealing, and it has indicated the clinical limitation of treatment with the Najuta stent graft. According to the suggestion from instructions for use, it seems better to avoid using it for patients with proximal neck length <20 mm.

In summary, the Najuta stent graft can be considered for use in patients at high risk for total arch replacement and surgical procedure for cerebral vessels by the debranched or chimney techniques, and with a proximal neck length >20 mm.

Although the clinical outcome of the present study is not better than other general TEVAR results, we have considered it almost acceptable as a less invasive treatment option for high-risk patients who are unable to undergo graft replacement. However, the surgical procedure for total arch replacement has been established and has shown improved clinical outcomes recently. Previous studies have reported a stroke rate of 2.4%–8.0%, an in-hospital mortality rate of 4.9%–5.4%, survival at 5 years of 70%–90.1%, and the rate of aorta-related events as 0%.\(^12,15\) These good results may suggest extending the indication of total arch replacement to high-risk patients. It will be necessary to select the surgical strategy in full consideration of these results.

There were several limitations in this retrospective, two-center study. Multivariate analysis was not performed owing to the small number of cases. Thus, statistical reliability may be insufficient. Furthermore, because the application of TEVAR was often judged depending on each operator, whether graft replacement was really impossible or not remains unknown. Improvements in the quality of analyzed data and prospective data accumulation for elimination of data bias are required.

**Conclusion**

We have summarized the long-term clinical outcomes of TEVAR using the Najuta stent-graft system. Although our results were not better because of the high incidence of type I endoleaks and aortic events in the chronic phase, we have considered TEVAR acceptable as a less invasive treatment option for high-risk patients who are unable to undergo graft replacement.

**Disclosure Statement**

The authors declare no conflict of interest.

**Author Contributions**

Writing: HS

Critical review and revision: all authors

Final approval of article: all authors

Accountability for all aspects of the work: all authors

**References**

1. Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. J Thorac Cardiovasc Surg 2007; 133: 369-77.e4.

2. Desai ND, Burch K, Moser W, et al. Long-term comparison of thoracic endovascular aortic repair (TEVAR) to open surgery for the treatment of thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2012; 144: 604-11; discussion, 609-11.

3. Manetta F, Newman J, Mattia A. Indications for thoracic endovascular aortic repair (TEVAR): a brief review. Int J Angiol 2018; 27: 177-84.

4. Ryomoto M, Tanaka H, Mitsuno M, et al. A novel approach to prevent perioperative stroke in patients undergoing debranching thoracic endovascular aortic repair with a mini-cardiopulmonary bypass support. Ann Vasc Surg 2019; 59: 143-9.

5. Iwakoshi S, Ichihashi S, Itoh H, et al. Clinical outcomes of thoracic endovascular aneurysm repair using commercially available fenestrated stent graft (Najuta endograft). J Vasc Surg 2015; 62: 1473-8.

6. Kawaguchi S, Shimizu H, Yoshitake A, et al. Endovascular stent graft repair for thoracic aortic aneurysms: the history and the present in Japan. Ann Vasc Dis 2013; 6: 129-36.

7. Kawaguchi S, Yokoi Y, Shimazaki T, et al. Thoracic endovas-
Clinical Outcomes of the Najuta Stent-Graft System

8) Yuri K, Yokoi Y, Yamaguchi A, et al. Usefulness of fenestrated stent grafts for thoracic aortic aneurysms. Eur J Vasc Surg 2008; 48 Suppl: 24S-95.

9) Yokoi Y, Azuma T, Yamazaki K. Advantage of a precurved fenestrated endograft for aortic arch disease: simplified arch aneurysm treatment in Japan 2010 and 2011. J Thorac Cardiovasc Surg 2013; 145 Suppl: S103-9.

10) Kanaoka Y, Ohki T, Maeda K, et al. Outcomes of chimney thoracic endovascular aortic repair for an aortic arch aneurysm. Ann Vasc Surg 2020; 66: 212-9.

11) Shahverdyan R, Gawenda M, Brunkwall J. Triple-barrel graft as a novel strategy to preserve supra-aortic branches in arch-TEVAR procedures: clinical study and systematic review. Eur J Vasc Endovasc Surg 2013; 45: 28-35.

12) Hiraoka A, Chikazawa G, Tamura K, et al. Clinical outcomes of different approaches to aortic arch disease. J Vasc Surg 2015; 61: 88-95.

13) Narita H, Komori K, Usui A, et al. Postoperative outcomes of hybrid repair in the treatment of aortic arch aneurysms. Ann Vasc Surg 2016; 34: 53-61.

14) Kurimoto Y, Maruyama R, Ujihira K, et al. Thoracic endovascular aortic repair for challenging aortic arch diseases using fenestrated stent grafts from zone 0. Ann Thorac Surg 2015; 100: 24-32; discussion, 32-3.

15) Khullar V, Schaff HV, Dearani JA, et al. Open surgical repair remains the gold standard for treating aortic arch pathology. Ann Thorac Surg 2017; 103: 1413-20.